Final-Program-ATS-2023-AP.vp

TUESDAY • MAY 23

221

pulmonary disease and tuberculosis (TB), and/or working in the field of NTM and/or TB Objectives At the conclusion of this session, the participant will be able to: • participants will be able to learn new diagnostic and therapeutic strategies, for the best management of patients with complex MAC and MAbsC-lung disease, including novel and emergent treatment interventions in the United States and abroad • participants will be able to learn new concepts from recent studies to optimally diagnose and manage latent, incipient, and subclinical TB infection in special settings in TB endemic areas and non-endemic areas • participants will be able to learn new concepts from recent studies to optimally diagnose and manage patients with TB and MDR-TB/pre-XDR-TB (and their contacts) based on recent WHO guidelines, ATS/IDSA guidelines, and recent clinical trials data This session will review recent translational and clinical data, including recent clinical trials results, to provide state of the art clinical perspective of new developments in prevention strategies, diagnostics and management of M. avium complex (MAC) and M. abscessus complex (MAbsC) lung disease, as well as of latent, incipient and subclinical TB infections, and multidrug-resistant TB in various groups of patients and settings. Chairing: P. Escalante, MD, MSc, Rochester, MN S.H. Kasperbauer, MD, Denver, CO A. Cattamanchi, MD, San Francisco, CA 9:00 MAC Pulmonary Disease: Evolving Concepts and Best Individualized Management C.L. Daley, MD, Denver, CO 9:20 M. Abscessus Complex Pulmonary Disease: Novel Treatment Interventions and Individualized Approach M.P. Dalcolmo, MD, PhD, Rio De Janeiro, Brazil 9:40 Diagnostics and Therapeutic Interventions in Latent, Incipient, and Subclinical TB Infections P. Escalante, MD, MSc, Rochester, MN 10:00 TB and MDR-TB: Evolving Concepts and Recent Guidelines-Based Therapies C.A. Haley, MD, MPH, Gainesville, FL 10:20 Questions and Answers This session and the International Conference are supported by an independent medical educational grant from Insmed Incorporated. All CME sessions have been planned and implemented in accordance with the Accreditation Criteria of the Accreditation Council for Continuing Medical Education (ACCME®) and are free of the control of ineligible companies (formerly commercial interests).

BEHAVIORAL • CLINICAL SCIENTIFIC SYMPOSIUM CME Credits Available: 1.5

C9 REHABILITATION FOR THE POST-COVID POPULATION Assemblies on Pulmonary Rehabilitation; Behavioral Science and Health Services Research; Critical Care 9:00 AM - 10:30 AM Walter E. Washington Convention Center Room 146 A-C (Street Level) Target Audience Clinicians and researchers working in the field of pulmonary rehabilitation who have extended or wish to extend their scope to include those with COVID-19, and clinicians caring for patients with COVID-19/ long COVID/ post-COVID syndrome Objectives At the conclusion of this session, the participant will be able to: • define the rationale for COVID-rehabilitation in terms of ongoing patient symptoms • better understanding of the evidence underpinning rehabilitation in the post-COVID population and other treatment approaches available in order to better advise patients on treatment options • utilize the most appropriate outcome measures in this field Attendees can expect to learn about the rationale and evidence underpinning the inclusion of patients recovering from COVID-19 in pulmonary rehabilitation (PR). This sessions will also debate if PR is the best intervention for this population or if other forms of rehabilitation/ other treatments are better placed. Chairing: R.A. Evans, MBChB, FRCP, PhD, Leicester, United Kingdom F. Franssen, MD, PhD, Horn, Netherlands 9:00 Rationale for Rehabilitation in the Post-COVID-19 Population (Long COVID Symptoms) M. Beauchamp, PT, PhD, Hamilton, Canada 9:15 Evidence for Post-COVID Exercise-Based Rehabilitation Programs S.J. Singh, PhD, Leicester, United Kingdom 9:30 Evidence for Fatigue Management in Long COVID T. Chalder, PhD, London, United Kingdom 9:45 Core Outcome Set for Long COVID D.M. Needham, MD, PhD, Baltimore, MD 10:00 Argument 1:Patients Recovering from COVID Should Be Integrated into Existing Pulmonary Rehabilitation Services R. Gloeckl, PhD, Schoenau am Koenigssee, Germany

ATS 2023 • Washington, DC